medigraphic.com
ISSN 1561-2988 (Print)

2012, Number 3

<< Back Next >>

Rev Cubana Farm 2012; 46 (3)

Oxidative stress indicators for HIV/AIDS patients with rheumatologic manifestations

Pomier SO, Gil VL, Rodríguez DF, Huetes MLR, Alerm GA, Bermúdez AY, Millán MJC

Language: Spanish
References: 41
Page: 329-342
PDF size: 96.20 Kb.


ABSTRACT

Introduction: the oxidative stress has been recognized as a cofactor in the progression of the human immunodeficiency virus (HIV) infection and in the rheumatologic manifestations.
Objective: to assess the oxidative stress indicators in those HIV patients with rheumatologic manifestations.
Methods: thirty one HIV patients with rheumatologic manifestations were studied and the evaluated indexes were compared to those of a control group made up of 31 apparently healthy individuals. The patients were classified according to the following activity criteria: scale of the disease activity for the rheumatologic manifestations, and index of disease activity and the analogical visual scale of pain at night in terms of the rheumatologic manifestations. The plasma concentrations of the oxidative stress indexes were measured by spectrophotometric techniques. Statistical analysis was made using SPSS 13 program.
Results: the evaluated HIV patients presented with moderate to severe oxidative stress, characterized by significant increase in the oxidative damage parameters and decrease in the antioxidizing systems (p< 0.05) after a comparison with those parameters of an apparently healthy control group in terms of age and gender. No statistically significance was found in the studies carried out to relate rheumatologic manifestations, time elapsed from the HIV confirmation, gender, CD4 lymphocyte T count and the viral load.
Conclusions: the collected data showed that the oxidative stress indicators could be useful in treating and following-up the HIV patients with rheumatologic manifestations.


REFERENCES

  1. UNAIDS Report on the Global AIDS Epidemic 2010. UNAIDS. Available from: http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2010 /20101123_globalreport_en.pdf

  2. Anuario estadístico de salud. Ministerio de Salud Pública. 2011. Disponible en: http://files.sld.cu/dne/files/2012/04/anuario-2011-e.pdf

  3. Muller-Ladner U, Kriegsmann J, Gay RE. Progressive joint destruction in human immunodeficiency virus-infected patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:1328-32.

  4. Berman A, Espinoza LR, Díaz JD, Aguilar JL, Rolando T, Vasey FB, et al. Rheumatic manifestations of human immunodeficiency virus infection. Am J Med. 1988;85:59-64.

  5. Yao Q, Frank M, Glynn M, Altman RD. Rheumatic manifestations in HIV-1 infected in-patients and literature review. Clin Exp Rheumatol. 2008;26:799-806.

  6. Murphy EL, Collier AC, Kalish LA, Assmann SF, Para MF, Flanigan TP, et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med. 2001;135(1):17-26.

  7. Centres for Disease Control and Prevention. Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents. MMWR 58 (No. RR-4) April 10, 2009. [AIDSinfo Web Site]. Available from: http://www.aidsinfo.nih.gov/Guidelines

  8. Nguyen BY, Reveille JD. Rheumatic manifestations associated with HIV in the highly active antiretroviral therapy era. Curr Opin Rheumatol. 2009;21(4):404-10.

  9. Vassilopoulos D, Calabrese LH. Virally associated arthritis 2008: clinical, epidemiologic, and pathophysiologic considerations. Arthritis Res Ther. 2008;10(5):215.

  10. Louthrenoo W. Rheumatic manifestations of human immunodeficiency virus infection. Curr Opin Rheumatol. 2008;20(1):92-9.

  11. Calabrese LH, Kirchner E, Shrestha R. Rheumatic complications of human immunodeficiency virus infection in the era of highly active antiretroviral therapy: emergence of a new syndrome of immune reconstitution and changing patterns of disease. Semin Arthritis Rheum. 2005;35:166-74.

  12. Dhasmana DJ, Dheda K, Ravn P, Wilkinson RJ, Meintjes G. Immune reconstitution inflammatory syndrome in HIV-Infected patients receiving antiretroviral therapy: pathogenesis, clinical manifestations and management. Drugs. 2008;68(2):191-208.

  13. Medina F, Pérez L, Moreno J. Rheumatic Manifestations of Human Immunodeficiency Virus Infection. Infect Dis Clin North Am. 2006;20:891-912.

  14. Kelly PV. Manifestaciones reumatológicas en pacientes infectados con virus de inmunodeficiencia humana. Acta Med Colomb. 2010;1:15-20.

  15. Márquez J, Restrepo CS, Candia L, Berman A, Espinoza LR. Human immunodeficiency virus associated rheumatic disorders in the HAART era. J Rheumatol. 2004;31:741-6.

  16. Zhang X, Li H, Li T, Zhang F, Han Y. Distinctive rheumatic manifestations in 98 patients with human immunodeficiency virus infection in China. J Rheumatol. 2007;34:1760-4.

  17. Pasupthi P, Ramachandran T, Sindhu PJ, Saravanan G, Bakthavathsalam G. Enhanced oxidative stress markers and antioxidant imbalance in HIV infection and aids patients. J Sci Res. 2009;1:370-80.

  18. Deaney CL, Feyi K, Fomest CM, Freeman A, Harman G, McDonald MS, et al. Levels of lipid peroxidation products in a chronic inflammation disorder. Rev Commun Mol Pathol Pharmacol. 2001;110:87-95.

  19. Bauerova K, Bezele A. Role of reactive oxygen and nitrogen species in ethiopathogenesis of rheumatoid arthritis. Gen Physiol Biophys. 1999;18:15-20.

  20. Ignatowicz E, Rybezynsda M. Some biochemical and pharmacological aspects of free radical-mediated tissue damage. Pol J Pharmacol. 1994;46:103-14.

  21. Sherwood L. Human physiology: from cells to systems. In: Belmont CA, editor. Textbook of Medical Physiology. London: Wadsworth Publishing Co; 2004.

  22. Filippin LI, Vercelino R, Marroni NP, Xavier RM. Redox signalling and the inflammatory response in rheumatoid arthritis. Clin Exp Immunol. 2008;152:415-22.

  23. Zwart LL, Meerman JHN, Commandeur JNM, Vermeulen NPE. Biomarkers of free radical damage. Applications in experimental animals and in humans. Free Rad Biol Med. 1999;26(1/2):202-26.

  24. Masiá M, Padilla S, Bernal E, Almenar MV, Molina J, Hernández I, et al. Influence of antiretroviral therapy on oxidative stress and cardiovascular risk: a prospective cross-sectional study in HIV-infected patients. Clin Therap. 2007;29(7):1448-55.

  25. Ozturd HS, Cimen MY, Cimen OB, Kacmaz M, Durak I. Oxidant/antioxidant status of plasma samples from patients with rheumatoid arthritis. Rheumatol Int. 1999;19:35-7.

  26. Kalpakcioglu B., Senel K. The interrelation of glutathione reductase, catalase, glutathione peroxidase, superoxide dismutase, and glucose-6-phosphate in the pathogenesis of rheumatoid arthritis. Clin Rheumatol. 2008;27:141-5.

  27. Muller F, Svardal AM, Nordoy I, Berge RK, Aukrust P, Froland SS. Virological and immunological effects of antioxidant treatment in patients with HIV infection. Eur J Clin Invest. 2000;30(10):905-14.

  28. Semba RD, Tang AM. Micronutrients and the pathogenesis of human immunodeficiency virus infection. Br J Nut. 1999;81:181-9.

  29. Anestt FA, Edworthy SM, Bloch DA. The American Rheumatism association 1987 revised criteria for the classification of Rheumatoid arthritis. Arthritis Rheum. 1988;31:315-24.

  30. Sedlak J, Lindsay RH. Estimation of total protein bound and non protein sulfhydryl group in tissue with Ellman´s reagent. Anal Biochem. 1968;25:192-205.

  31. Erdelmeier I, Gerard MD, Yadan JC, Chaudiere J. Reactions of N methyl-2-phenylindole with malondialdehyde and 4-hydroxialkenals. Mechanistic aspects of the colorimetric assay of lipid peroxidation. Chem Res Toxicol. 1998;11(10):1184-94.

  32. Ozdemirler G, Mehmetcik G, Oztezcan S, Toker G, Sivas A, Uysal M. Peroxidation potential and antioxidant activity of serum in patients with diabetes mellitus and myocardial infarction. Metab Res. 1995;271:194-6.

  33. Witko-Sarsat V, Friedlander M. Advanced oxidation protein product as novel mediators of inflammation and monocytes activation in chronic renal failure. J Immunol. 1998;161:2524-32.

  34. McCord JM, Fridovich I. The reduction of cytochrome C by milk xanthine oxidase. J Biol Chem. 1968;243:5753-60.

  35. Clairborne A. Catalase activity. En: Green-Wald RA, ed. Handbook of Methods for Oxygen Radical Research. Boca Ratón, FL: CRC Press Inc; 1986. p. 283-4.

  36. Winchester R, Bernstein DH, Fisher HD, Enlow R, Solomon G. The co-ocurrence of Reiter´s syndrome and acquired immunodeficiency. Ann Intern Med. 1987;106:19-26.

  37. Reino Buelvas A, Vásquez Duque G. Manifestaciones reumáticas de la infección por el virus de inmunodeficiencia humana (VIH). IATREIA. 2005;18:185-98.

  38. Njobvu P, McGill P. Human immunodeficiency virus related reactive arthritis in Zambia. J Rheumatol. 2005;32:1299-304.

  39. Walker U A, Tyndall A, Daikeler T. Rheumatic conditions in human immunodeficiency virus infection. Rheumatology. 2008;47:952-9.

  40. Gil L, Martínez G, González I, Tarinas A, Álvarez A, Giuliani A, Molina R, Pérez J. Contribution to characterization of oxidative stress in HIV/AIDS patients. Pharmacol Res. 2003;47:217-24.

  41. French MA, Price P. Immune restoration disease in HIV-infected patients after antiretroviral therapy. Clin Infect Dis. 2001;32:325-6.




2020     |     www.medigraphic.com